# Cross-session log — Wave 3 dispatch — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director [a2c0d8]`)

## Trigger

PI authorization to open Wave 3 (Synthesis) for this project/run. Scope: `40_SYNTHESIS/` authorized;
`50_MANUSCRIPT/` explicitly NOT authorized this wave. All work (Director + peers) on model sonnet.

## Pre-dispatch health check

`ListAgents` called fresh at Wave 3 start. Result: this session confirmed as the **sole** live
`pit-eze-research-director` [a2c0d8] — an earlier documentation-only note (in
`SESSION-REGISTRY.md`'s post-Gate-2 update) had flagged a possible second Director-named session as
a transient artifact of a session resume; re-checked now and resolved (only one Director session is
live). Peers reachable by name: `pit-eze-guideline-risk` [89b096] (very recently (re)started, ~1m
old at check time — treated as a fresh resume, given its own resume prompt in the dispatch message),
`pit-eze-trials-efficacy` [1a2045] (started ~31m before check), `pit-eze-safety-pharmacology`
[5c9140] (same long-running session since Wave 2, ~6h old). No replacement identities created —
existing names used directly (Golden Rule 1).

## Director branch catch-up

Local `main` was 17 commits ahead of this session's branch (containing, among other things,
`pit-eze-trials-efficacy`'s own `76f4f51` fulltext-repair commit merged directly into `main`).
Merged `main` into `worktree-wave0-init` via the established safe pattern (same-branch catch-up, not
a branch-consolidation act) — no push or merge of `main` itself. Brought in the specialists' actual
Wave 2 extraction tables, evidence maps, DDI matrix, and fulltext-manifest files for direct Director
visibility.

## OpenEvidence tool check

`openevidence` MCP remains disconnected in this session (`CONNECTION_CLOSED`); a `ToolSearch` for
`oe_health`/`oe_auth`-class tools returned no match. Recorded as a tool blocker, not a project
blocker — Wave 3 proceeds on lawful PubMed/PMC/Crossref/Unpaywall/paper-search/`research_hub`
metadata-search paths. Each dispatched specialist was told: if *its own* session has a working
OpenEvidence relay, it may run **at most one bounded discovery pass** on its own still-blocked
sources — discovery/corroboration only, never a primary-source substitute, and must not weaken any
`BLOCKED_FOR_SOURCE` status absent an independently obtained lawful primary source.

## Dispatch (three `TASK_ASSIGNMENT` messages sent via real `SendMessage`)

- **trials-efficacy**: T-024 (Abbas 2026) full text/extraction first, then T-023 (Lu 2026); build
  the Level 1/2/3 hard-outcome distinction explicitly, without conflating RACING/HIJ-PROPER/
  REPRIEVE/REAL-CAD; bounded OpenEvidence pass on #33 authorized if available.
- **safety-pharmacology**: Singh 2024 (T-003) RCT-vs-observational disaggregation (parallel risk to
  the PI-decided Sydhom framing); deepen T-025 if possible (T-009 already fully verified, told not
  to redo); search for FDC-specific CKD dosing and pitavastatin-specific BCRP quantitative data;
  preserve calibrated NODM/DDI language; bounded OpenEvidence pass on T-005/CKD-dosing gap
  authorized if available.
- **guideline-risk**: resume-prompt reminder given (session was very recently restarted); #29
  full-text thresholds, T-008 (Taiwan health-promotion annual report) direct-fetch attempt, exact
  guideline wording only via lawful paths; the six already-blocked sources preserved as-is, no
  re-attempt without new instruction; bounded OpenEvidence pass on its own three blocked sources
  (T-005, T-006, #34) authorized if available.

**Common instructions to all three**: confirm model sonnet; full provenance (license/URL/timestamp/
SHA-256/parse-status/locators) for any lawful full text obtained; PDFs gitignored, never committed;
write only to owned paths; report via the standard message schema.

## Governance files updated this turn

`05_STATUS.md` (Wave 3 opened, Gate 2 state preserved above it), `03_DECISION-LOG.md` (Decision
2026-08-31-28), `00_RUN-MANIFEST.md` (Wave 3 pointer note, additive), `04_OPEN-QUESTIONS.md` (T-023/
T-024 marked dispatched rather than held), this log entry.

## Status

Wave 3 dispatched to all three specialists. Awaiting completion reports before Director integration
into `40_SYNTHESIS/`. Deliverables required this wave (per PI spec): executive clinical synthesis,
claim-evidence matrix, guideline/risk-positioning section, LDL efficacy/dose-escalation section,
CV-outcomes hierarchy, glycemic/safety/DDI/CKD section, adherence/residual-risk section, limitations/
open gaps, number/claim/citation traceability table — Traditional Chinese prose with English drug/
technical names, causal language only where evidence supports it. Sequence after specialist reports:
Director integration → Director Wave 3 Challenge Round → Gate 3 internal-consistency check → if
passed, Wave 4 independent audit (sonnet, read-only except `99_FINAL-QA.md`).
